The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Interferon Score Predicts AI-CTDs

Interferon Score Predicts AI-CTDs

November 18, 2018 • By Susan Bernstein

  • Tweet
  • Email
Print-Friendly Version / Save PDF
Representation of the molecular structure of interferon a.

Representation of the molecular structure of interferon a.
Kateryna Kon / shutterstock.com

People with autoimmune connective tissue diseases produce antibodies against nuclear antigens up to 10 years before they develop clinical features. Anti-nuclear antibodies (ANAs) are also very common, and a small percentage of ANA-positive patients progress to clinical autoimmunity.

You Might Also Like
  • Rontalizumab May Help Patients with Lupus & Low Interferon Signature
  • Research Targets Interferon Alpha in New Treatment Approach for CNS Lupus
  • Bipolar Disorder, Nailfold Capillaroscopy Score, Urban Location Among Risk Factors for Developing Lupus
Explore This Issue
November 2018
Also By This Author
  • Rheumatology Research Clears Paths to Improved Arthritis Patient Care, Long-Term Health

The question: Is there a reliable way to screen at-risk patients before they develop active autoimmunity and identify those most likely to progress?

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

In a new study published in the Annals of the Rheumatic Diseases, researchers at the University of Leeds Institute of Rheumatic and Musculoskeletal Medicine, England, show that a novel, two-factor interferon-stimulating gene (ISG) score, along with a family history of autoimmune rheumatic disease, predicts the progression from ANA positivity to an active autoimmune connective tissue disease (AI-CTD).1 This test could allow rheumatologists to screen at-risk patients and recommend early intervention during the subclinical autoimmunity phase. The Leeds Institute researchers are now working to replicate and validate their findings in a second cohort.

There remains a significant need for an accurate, predictive test for likely progression to autoimmunity in this patient population, says Md Yuzaiful Md Yusof, MBChB, MRCP, a rheumatologist and doctoral research fellow at the University of Leeds, and one of the study’s co-authors. The researchers’ primary goal was to find a reliable test to stratify patients at highest risk for progression and allow for early treatment to help prevent irreversible tissue damage, and reduce the need for remission induction therapy with glucocorticoids. AI-CTDs include such diseases as systemic lupus erythematosus, primary Sjögren’s syndrome, systemic sclerosis (SSc), inflammatory myopathies and mixed and undifferentiated CTDs.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

“ANA positivity, as detected from a blood test, is a common finding. However, only less than 1% of individuals with a positive test progress into autoimmune connective tissue disease,” says Dr. Yusof. Because there are “limited data on reliable predictors of progression, some of these individuals may be discharged prematurely after the first consultation if they do not meet the criteria of an AI-CTD. Although it may not be cost effective to follow up all these individuals routinely in clinic, the risk of premature discharge from secondary care can lead to a delay in diagnosis, and, should they progress, this can result in damage accrual and development of comorbidities.”

Dr. Yusof

Dr. Yusof

‘By screening ANA-positive individuals for the two predictors of progression identified in our study—IFN scores & a positive family history of autoimmune rheumatic diseases—those with the imminent risk of relapse can be offered early treatment to prevent severe organ involvement, organ damage & glucocorticoid use.’ —Dr. Yusof

The Interferon Pathway

The researchers focused on variants in the type-1 interferon (IFN-1) pathway because of their prominent (if still unclear) role in patients’ genetic susceptibility to AI-CTDs. In an earlier study, these researchers described a novel system using two interferon-stimulated gene (ISG) expression scores, ISG-Score-A and ISG-Score-B, which in combination identify clinically meaningful differences in interferon status between and within autoimmune diseases.2 In the current study, they set out to apply the scoring system to predict progression from at-risk status to AI-CTD.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

AI-CTDs most often affect the joints and the skin, the researchers write. Although musculoskeletal ultrasound can detect subclinical synovitis in lupus, and skin biopsies can show differences in interferon gene expression in cutaneous lupus, neither test has been assessed in at-risk individuals.3,4

Pages: 1 2 3 | Single Page

Filed Under: Conditions, Research Reviews, Soft Tissue Pain Tagged With: connective tissue diseaseIssue: November 2018

You Might Also Like:
  • Rontalizumab May Help Patients with Lupus & Low Interferon Signature
  • Research Targets Interferon Alpha in New Treatment Approach for CNS Lupus
  • Bipolar Disorder, Nailfold Capillaroscopy Score, Urban Location Among Risk Factors for Developing Lupus
  • Low Blood Pressure Increases Risk of Death in Patients with Systemic Sclerosis-Associated Pulmonary Arterial Hypertension

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)